docetaxel anhydrous has been researched along with carboplatin in 648 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (2.93) | 18.2507 |
| 2000's | 271 (41.82) | 29.6817 |
| 2010's | 305 (47.07) | 24.3611 |
| 2020's | 53 (8.18) | 2.80 |
| Authors | Studies |
|---|---|
| Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y | 1 |
| Berille, J; Fossella, FV; Hong, WK; Lee, JS | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Balmaceda, C; Barakat, R; Francis, P; Hakes, T; Hann, L; Phillips, M; Schneider, J | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Harper, P | 1 |
| Hortobagyi, GN | 1 |
| Belani, CP | 5 |
| Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Criée, CP; Dalichau, H; Griesinger, F; Hannemann, P; Hemmerlein, B; Herse, B; Hess, CF; Hiddemann, W; Schmidberger, H; Wörmann, B | 1 |
| Armand, JP; Couteau, C | 1 |
| de Graaff, M; Floot, BJ; Maliepaard, M; Pluim, D; Schellens, JH; Slaper-Cortenbach, IC | 1 |
| Edelman, MJ; Gandara, DR; Lau, D | 1 |
| Engblom, P; Grènman, S; Kulmala, J; Rantanen, V | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Belani, CP; Fossella, F; Rigas, JR | 1 |
| Amorino, GP; Choy, H; Hamilton, VM | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
| Burris, HA; Erland, JB; Gray, J; Greco, FA; Hainsworth, JD; Hermann, RC; Morrissey, LH; Steis, R; Thompson, D | 1 |
| Agelaki, S; Androulakis, N; Dimou, T; Georgoulias, V; Giannakakis, T; Hatzidaki, D; Kakolyris, S; Mavroudis, D; Parashos, M; Sarra, E; Vlachonikolis, J; Ziras, N | 1 |
| Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H | 1 |
| Berille, J; Burkes, R; Coughlin, S; Dancey, J; Gralla, R; Gressot, L; Kim, Y; Levitan, N; Mattson, K; O'Rourke, M; Ramlau, R; Shepherd, FA; Vincent, M | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
| Belani, CP; Bonomi, P; Capozzoli, MJ; Cohen, LJ; Dobbs, T; Earhart, R; Einzig, A; Luketich, JD | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Sandler, A | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Atkinson, R; Coleman, R; Crawford, M; Cruickshank, M; Eggleton, P; Fleming, D; Graham, J; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Vasey, PA | 1 |
| Braess, J; Friedrichsen, S; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Belani, C; Lynch, T | 1 |
| Crown, JP | 1 |
| Bittner, C; Feyerabend, T; Peters, SO; Raap, M; Remmert, S; Robins, IH; Sieg, P; Sommer, K; Wiedemann, GJ | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Ratain, MJ; Sawyer, M | 1 |
| Kato, Y; Nosaka, S; Tamura, K; Tumori, M; Yamane, Y; Yamauti, M | 1 |
| Belani, C | 1 |
| Bando, H; Miyata, J; Sano, T; Sumitomo, M | 1 |
| Kaye, SB | 1 |
| Murren, JR | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Delprino, L; Recalenda, V; Rocco, F; Tagini, V | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Choy, H; DeVore, RF; Hande, KR; Johnson, DH; Laporte, K; Porter, LL; Rosenblatt, PA; Shyr, Y; Slovis, B | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Caffo, O | 1 |
| Kobina, S; Moyano, A; Rubio-Terrés, C; Tisaire, JL | 1 |
| Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G | 1 |
| Doi, S; Fukuda, M; Kanda, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Soda, H; Suenaga, M; Takatani, H; Tsurutani, J | 1 |
| Morere, JF | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Davis, JA; Kaye, SB; O'Neill, VJ; Paul, J; Reed, NS; Vasey, PA | 1 |
| Dierlamm, T; Dürk, H; Fiedler, W; Knuffmann, C; Kurt Hossfeld, D; Laack, E; Popp, J; Schmied, B; Verpoort, K; Wacker-Backerhaus, G; Zeller, W | 1 |
| Shepherd, FA | 1 |
| Kato, H; Tsuboi, M | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Kato, Y; Kitagaki, H; Maruyama, R; Nishiki, M; Tumori, M; Uchida, N; Yamane, Y; Yamauti, M; Yoshida, M | 1 |
| Culine, S | 1 |
| Takigawa, N | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Khuri, FR; Kim, ES | 1 |
| Potter, DM | 1 |
| Ikeda, H; Koshiba, R; Ohsawa, H; Tanaka, A | 1 |
| Krüger, I; Lindenfelser, R; Scherwitz, P | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Blohmer, JU; Breidenbach, M; Göhring, UJ; König, E; Kurbacher, CM; Mallmann, P; Rein, DT; Schmidt, T; Schöndorf, T | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Belani, CP; Langer, C | 1 |
| Postmus, P | 1 |
| Odagiri, K; Okami, K; Onuki, J; Sakai, A; Takahashi, M | 1 |
| Fujimura, M; Iwasa, K; Kasahara, K; Kimura, H; Myo, S; Nakao, S; Nishi, K; Shibata, K; Shintani, H; Shirasaki, H; Yasuda, U | 1 |
| Bishop, JF; Boyer, MJ; Clarke, S; Goh, BC; Lehnert, M; McNeil, E; Millward, MJ; Rischin, D; Wong, J | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Matsushita, H; Obata, H; Tanaka, K; Watanabe, M; Yahata, T | 1 |
| Agelaki, S; Alexopoulos, A; Androulakis, N; Ardavanis, A; Bozionelou, V; Georgoulias, V; Kandylis, C; Kouroussis, Ch; Malamos, N; Mavroudis, D; Stavrinidis, E | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Berman, SM; Choi, NC; Fidias, P; Herbst, RS; Jänne, PA; Johnson, BE; Lucca, J; Lukanich, JM; Lynch, C; Mathisen, DJ; Ostler, P; Skarin, AT; Sugarbaker, DJ; Wirth, LJ | 1 |
| McGuire, WP | 1 |
| Vasey, PA | 1 |
| Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
| Scagliotti, GV; Turrisi, AT | 1 |
| Markman, M | 2 |
| Cruickshank, ME; Delaney, E; Hutcheon, AW; McNally, OM; Parkin, DE; Petty, RD | 1 |
| Fukaya, T; Maeda, N; Oguri, H | 1 |
| Hirata, Y; Imanishi, K; Kaku, M; Kobayashi, A; Murao, S; Ohara, N; Seima, Y; Tomura, N; Yamasaki, M | 1 |
| Hiroi, M; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Asano, K; Fukunaga, K; Hasegawa, N; Nakamura, H; Oyamada, Y; Watanabe, H; Yamaguchi, K | 1 |
| Katsumata, N | 1 |
| Godley, PA; Halabi, S; Kelly, WK; Oh, WK; Small, EJ; Vogelzang, NJ; Werner, C | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Kazumoto, T; Kobayashi, K; Komagata, H; Kosaihira, S; Saito, Y; Sakai, H; Yoneda, S | 1 |
| Hsu, Y; Sood, AK; Sorosky, JI | 1 |
| Belinson, J; Kulp, B; Markman, J; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Brumfield, B; Clayman, G; Diaz, EM; Garden, A; Glisson, BS; Johnson, FM; Khuri, FR; Kies, M; Morrison, W; Palmer, JL; Papadimitrakopoulou, V | 1 |
| Blohmer, JU; du Bois, A; Hilpert, F; Pfisterer, J; Quaas, J; Wagner, U; Wallwiener, D | 1 |
| Ray-Coquard, I | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Cortesina, G; Danova, M; Gabriele, AM; Giordano, C; Pedani, F; Porta, C; Recalenda, V; Tagini, V | 1 |
| Griesinger, F; Haase, D; Metz, M; Schulz, T; Trümper, L | 1 |
| Cardaci, V; Cesario, A; D'Angelillo, RM; Galetta, D; Granone, P; Margaritora, S; Porziella, V; Russo, P; Sterzi, S; Trodella, L | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Belani, CP; Bonomi, P; Cascino, M; Dobbs, TW; Einzig, AI; Ramalingam, S; Wojtowicz-Praga, S | 1 |
| Sledge, GW | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Le Cesne, A; Le Guen, Y | 1 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Misawa, A; Misawa, H; Saitou, M; Ueta, K; Yasuda, M | 1 |
| Dempsey, DT; Furukawa, S; Gupta, D; McClurken, JB; Piacentino, V; Ross, K; Stepnowski, D | 1 |
| Arné-Bès, MC | 1 |
| Boezen, HM; Groen, HJ; van Putten, JW; Wachters, FM | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Lin, DX; Miao, XP; Tan, W; Wang, ZH; Xu, BH; Zhang, XR | 1 |
| Furugen, Y; Hata, A; Hata, N; Hata, Y; Kurokawa, A; Mitsuhashi, N; Nishihara, S; Sone, Y | 1 |
| Clouse, T; Geisler, JP; Gudenkauf, TJ; Linnemeier, G; Manahan, KJ; Wiemann, MC | 1 |
| Chuman, H | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Jeremic, B; Molls, M; Nieder, C; Zimmermann, F | 1 |
| Misawa, H; Ochiai, K; Tanaka, T; Yasuda, M | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Reddy, KG | 1 |
| Herzog, TJ | 1 |
| Huober, J; Mueck, AO; Seeger, H; Wallwiener, D | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| George, DJ; Gilligan, TD; Hagmann, E; Jacobson, JO; Kantoff, PW; Kaufman, DS; Manola, J; Oh, WK; Smith, MR | 1 |
| Sugiyama, T | 1 |
| Belani, CP; Eckardt, J | 1 |
| Dumontet, C; Sève, P | 1 |
| Fujiwara, K; Ishikawa, H; Kohno, I; Koike, H; Nagao, S; Oda, T; Tanaka, H | 1 |
| Iba, T; Kanamori, Y; Kigawa, J; Oishi, T; Shimada, M; Terakawa, N; Watanabe, A | 1 |
| DeZarraga, F; Doliny, P; Gomez, C; Hurley, J; Powell, J; Reis, I; Silva, O; Velez, P; Welsh, C | 1 |
| Barón, AE; Bearman, SI; Cagnoni, PJ; Gustafson, D; Jones, RB; Long, M; Matthes, S; McSweeney, PA; Nieto, Y; Shpall, EJ | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Kuzuya, T; Minami, H; Saka, H; Sakai, S; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Anderson, L; Anzai, Y; Boyd, C; Buelna, R; Canby, R; Donahue, M; Hutson, J; Keegan, K; Montgomery, RB; Schwartz, DL; Yueh, B | 1 |
| Bagaméri, A; Lehoczky, O; Pulay, T; Sárosi, Z; Thurzó, L; Udvary, J | 1 |
| Chiudinelli, F; Colombo, N; Fanucchi, A; Gadducci, A; Landoni, F; Lapresa, M; Maggino, T; Maria Ferrero, A; Sartori, E; Zola, P | 1 |
| Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Fujimi, A; Kato, J; Kuribayashi, K; Matsunaga, T; Murase, K; Niitsu, Y; Sakai, T; Sasaki, A; Satoh, M; Takimoto, R; Tateno, K; Terui, T; Wada, Y | 1 |
| Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Kuhn, JG; Raefsky, EL; Thompson, DS; White, MB; Willcutt, NT | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Martin, MC; Ngo, H; Smith, JA; Wolf, JK | 1 |
| Argiris, A; Jayaram, P; Pichardo, D | 1 |
| George, DJ; Oh, WK; Tay, MH | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Haura, E; Rocha-Lima, C; Simon, G; Wagner, H; Williams, C | 1 |
| Au, JL; Lu, Z; Wientjes, TS | 1 |
| Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY | 1 |
| Busse, PM; Goguen, L; Guadagnolo, BA; Haddad, RI; Norris, CM; Posner, MR; Sullivan, CA; Tishler, R; Weeks, L; Wirth, LJ | 1 |
| Addo, FK; Cole, JT; Fitch, TR; Flynn, PJ; Ingle, JN; Mailliard, JA; Perez, EA; Suman, VJ; Veeder, MH; Walsh, DJ | 1 |
| Chu, Q; Evans, WK; Logan, D; Mackay, JA; Vincent, M | 1 |
| Bunn, P; Kelly, K; Magree, L; Rabinovitch, R; Sunpaweravong, P | 1 |
| Ambrózay, E; Boross, G; Gyánti, R; Hajnal, L; Lorincz, M; Maráz, R; Markó, L; Svébis, M; Szucs, M; Vizhányó, R | 1 |
| Dimitrakopoulos, A; Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Polyzos, A; Spyropoulos, K; Tsavaris, N; Tzelepis, G | 1 |
| Bando, E; Endou, Y; Kawamura, T; Miyamoto, K; Sasaki, T; Shimada, T; Tanaka, M; Tochiori, S; Yonemura, Y | 1 |
| Fujii, M | 1 |
| Itamochi, H; Kanamori, Y; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Terakawa, N | 1 |
| Ramalingam, S | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| Inata, J; Kai, T; Kuraoka, T; Miyazaki, K; Murai, H; Tomoda, Y; Yamaoka, N | 1 |
| Bouchet, LG; Bova, FJ; Buatti, JM; Haller, J; Meeks, SL; Pennington, EC; Ryken, TC; Traynelis, V | 1 |
| Adami, G; Belvedere, O; Ceschia, T; Fasola, G; Grossi, F; Meduri, S; Recchia, L; Rizzato, S; Rossetto, C; Sacco, C; Sibau, A; Spizzo, R; Tumolo, S; Vigevani, E | 1 |
| Charoentum, C; Chewaskulyong, B; Munprakan, S; Soorraritchingchai, S; Thongprasert, S | 1 |
| Anderson, H; Ashcroft, L; Baka, S; Booton, R; Dark, G; Dunlop, D; Laurence, V; Lorigan, P; Nicolson, M; O'Brien, M; O'Byrne, K; Snee, M; Thatcher, N | 1 |
| Gotou, T; Kawashima, S; Kawashima, T; Kikkawa, K; Kuroda, T; Matsuzawa, Y; Nishi, Y; Shirai, K; Tanabe, M | 1 |
| Asmar, L; Brooker, R; Conkling, P; Ilegbodu, D; Lindquist, D; Sandbach, J; Vellek, M; Weissman, CH | 1 |
| Bandou, E; Endou, Y; Sasaki, T; Sawa, T; Sugarbaker, PH; Yonemura, Y; Yoshimitsu, Y | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Andritzky, B; Bokemeyer, C; Brandl, S; Goern, M; Laack, E; Schuch, G; Thoem, I | 1 |
| Busse, PM; Case, M; Costello, R; Goguen, L; Haddad, RI; Mahadevan, A; Norris, CM; Posner, MR; Sammartino, D; Stowell, S; Sullivan, C; Tishler, RB; Wirth, LJ | 1 |
| Soria, JC | 1 |
| Brown, R; Gifford, G; King, CR; Marsh, S; McLeod, HL; Paul, J | 1 |
| Katakami, N | 1 |
| Ara, G; Jeffers, M; LaRochelle, WJ; Lichenstein, HS; Petersen, KD; Qian, X; Sehested, M; Thougaard, A; Wu, F | 1 |
| Aoki, H; Arai, Y; Endoh, M; Ishidoya, S; Ito, A; Shimazui, T | 1 |
| Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A | 1 |
| Baumgart, A; Henze, A; Karbe, I; Koelbl, H; Strauss, HG; Teichmann, A; Thomssen, C | 1 |
| Fortner, BV; Houts, AC; Schwartzberg, LS | 1 |
| Boswell, JS; Flam, MS; Tashjian, DN; Tschang, TP | 1 |
| Borden, E; Bukowski, R; Cline-Burkhardt, M; Davis, M; Dowlati, A; Dreicer, R; Kalmadi, S; Mekhail, T; O'Keefe, S; Pelley, RJ | 1 |
| Aitini, E; Bajetta, E; Bidoli, P; Cortinovis, D; Cullurà, D; Formisano, B; Isa, L; Mancin, M; Mariani, L; Nova, P; Pari, F; Zilembo, N | 1 |
| Asada, M; Fuji, H; Inoue, D; Kanda, A; Kaneta, T; Kondo, T; Nakayama, K; Okinaga, S; Sasaki, H; Sasaki, T; Suzuki, S; Suzuki, T; Takai, Y; Watanabe, M; Yamanda, S; Yamaya, M; Yanagihara, K; Yasuda, H; Yoshida, M; Zayasu, K | 1 |
| Arichi, N; Hiraoka, T; Hyuga, T; Igawa, M; Kikuno, N; Kishi, H; Nakamura, S; Shigeno, K; Shiina, H; Sumura, M; Urakami, S; Wake, K; Yoneda, T | 1 |
| Tombal, B | 1 |
| Ancona, E; Boso, C; Chiarion-Sileni, V; Corti, L; Del Bianco, P; Innocente, R; Mazzarotto, R; Pigozzo, J; Ruol, A; Tomassi, O | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Bailey, HH; Connor, JP; Fine, J; Harris, LS; Hartenbach, EM; Kushner, DM; Sanchez, F; Schink, JC; Stewart, SL; Volk, M | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Sunaga, N; Tsuchiya, S; Watanabe, S; Yanagitani, N | 1 |
| Ideguchi, H; Ishigatsubo, Y; Ohno, S; Ueda, A | 1 |
| Coleman, RL; Crotzer, DR; Gershenson, DM; Levenback, CF; Sun, CC; Wolf, JK | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
| Ono, A; Yamamoto, N | 1 |
| Hasegawa, Y; Inoue, A; Ishida, T; Ishimoto, O; Koinumaru, S; Miki, H; Munakata, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Hanna, WT; Hubner, KF; Long, MJ; Nahmias, C; Townsend, DW; Wahl, LM | 1 |
| Arnould, L; Bleuse, JP; Campone, M; Chollet, P; Coeffic, D; Coudert, BP; Gligorov, J; Largillier, R; Martin, X; Namer, M; Priou, F; Serin, D; Trillet-Lenoir, V; Vasseur, B; Weber, B | 1 |
| Li, QY; Ma, SL; Yu, XM; Zhu, LM | 1 |
| Geisler, JP; Linnemeier, GC; Manahan, KJ; Thomas, AJ | 1 |
| Fujita, H; Honjo, H; Hosokawa, K; Kato, Y; Kinoshita, Y; Kuroboshi, H; Mori, T; Nakata, Y; Watanabe, A; Yamaguchi, T; Yasuda, J | 1 |
| Bookman, MA | 1 |
| Bagchi, S | 1 |
| Aravantinos, G; Fountzilas, G; Gogas, H; Kalofonos, HP; Klouvas, G; Kosmidis, P; Makatsoris, T; Papakostas, P; Pectasides, D; Tsavdaridis, D; Xanthakis, I | 1 |
| Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Ashcroft, L; Booton, R; Heighway, J; Morris, J; Thatcher, N; Ward, T | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L | 1 |
| Beer, TM; Bubley, GJ; Huang, J; Jacobus, S; Oh, WK; Ross, RW; Ryan, CW; Taplin, ME | 1 |
| Ferrell, B; Leong, L; Lowe, T | 1 |
| Jacobus, S; Kantoff, PW; McKearn, D; Nakabayashi, M; Oh, WK; Regan, MM; Ross, RW; Sartor, O; Taplin, ME | 1 |
| Charpidou, A; Dilana, K; Karapanagiotou, EM; Kosmas, E; Kotteas, E; Provata, A; Syrigos, K; Tourkantonis, I; Tzannou, I | 1 |
| Bidzinski, M; Kraszewska, E; Kupryjanczyk, J; Madry, R; Markowska, J; Stelmachow, J; Timorek, A; Ziolkowska-Seta, I | 1 |
| Alberola, V; Esteban, E; Juan, O; Sotillo, J | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Atkins, JN; Crane, JM; Detterbeck, FC; Harper, HD; Hensing, TA; Moore, DT; Socinski, MA; Stinchcombe, TE; Willard, EM | 1 |
| Bhide, SA; Harrington, KJ; Nutting, CM | 1 |
| Pajak, TF; Ridge, JA; Trotti, A | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Alexandrova, EN; Istomin, YP; Petrovich, SV; Sergeyeva, OP; Zhavrid, EA | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
| Cavaletti, G; Marmiroli, P; Nicolini, G | 1 |
| Blackwell, K; Bullock, K | 1 |
| Bamias, A; Briasoulis, E; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Karina, M; Koutras, A; Pavlidis, N; Pentheroudakis, G; Samantas, E; Samelis, G; Xiros, N | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Ishizaka, A; Matsuzaki, T; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Al-Adhami, M; Albert, G; Gravenor, D; Hirsh, V; Krieg, AM; Leichman, CG; Manegold, C; Mezger, J; Readett, D; Woytowitz, D | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Ross, HJ; Seung, SK | 1 |
| Beesley, J; Brown, R; Byth, K; Chenevix-Trench, G; DeFazio, A; Fereday, S; Harnett, PR; Johnatty, SE; Marsh, S; McLeod, H; Paul, J; Spurdle, AB; Webb, PM | 1 |
| Abiko, T; Koizumi, S; Takanami, I | 1 |
| Bobokova, J; Calles Blanco, A; Custodio Carretero, AB; Díaz-Rubio García, E; García Paredes, B; García Sáenz, JA; González Larriba, JL; Hernando Trancho, F; Rodríguez Lajusticia, L | 1 |
| Belani, CP; Butler, EH; Guidice, RA; Marsland, TA; Ramalingam, SS; Schreeder, MT; Steis, RG | 1 |
| Adisen, E; Benekli, M; Buyukberber, S; Coskun, U; Gureli, M; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Kraszewska, E; Kupryjańczyk, J; Madry, R; Rembiszewska, A; Szymańska, T; Timorek, A; Ziółkowska-Seta, I | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Bromund, JL; Chen, R; Dakhil, SR; Fidias, PM; Gill, J; Hristova-Kazmierski, M; Loesch, DM; Lyss, AP; Marciniak, M; Obasaju, CK; Schiller, JH; Treat, J; Waterhouse, DM | 1 |
| Kendrick, JE; Kilgore, LC; Matthews, KS; Numnum, TM; Shipman, KA; Straughn, JM; Whitworth, JM | 1 |
| Clynes, M; Corkery, B; Crown, J; O'Donovan, N | 1 |
| Asai, K; Hirata, K; Ichimaru, Y; Kimura, T; Kodama, T; Kudoh, S; Kyoh, S; Mitsuoka, S; Tochino, Y; Yana, T; Yoshimura, N | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Kalbakis, K; Kalykaki, A; Mavroudis, D; Vamvakas, L | 1 |
| Bossi, A; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C | 1 |
| Chung, HH; Kang, SB; Kim, HS; Kim, JW; Kim, MK; Park, NH; Song, YS | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR | 1 |
| Moro-Sibilot, D; Sculier, JP | 1 |
| Reck, M | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Choy, H; Dobbs, T; Dowlati, A; Hughes, RS; Jain, AK; Muldowney, NJ; Sandler, AB; Schlabach, L; Schwartzberg, LS; Wu, J | 1 |
| Greco, FA; Spigel, DR | 1 |
| Kovel, S; Sella, A; Yarom, N; Zisman, A | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Alberola, V; Arellano, A; Cardenal, F; Dómine, M; Garrido, P; Maeztu, I; Massutí, B; Ramos, A; Rosell, R | 1 |
| Argonza-Aviles, E; Ericson, SG; Gajra, A; Pandya, KJ; Warsi, GM; Wozniak, AJ | 1 |
| Cui, Y; Feng, K; Liu, ZJ; Qi, DL; Qiao, YF; Wang, QS; Xin, L; Yang, YZ | 1 |
| Corry, P; Moros, EG; Peñagarícano, JA; Ratanatharathorn, V; Yan, Y | 1 |
| García-Donas Jiménez, J; Jara Sánchez, C; Olier Gárate, C; Peñalver Párraga, J | 1 |
| Braun, M; Breitbach, GP; Diedrich, K; Hilfrich, J; Höss, C; Karbe, I; Kuhn, W; Leutner, C; Mahner, S; Möbus, V; Ortmann, O; Pölcher, M; Rudlowski, C; Schwarz, J; Stimmler, P | 1 |
| Ahn, YM; Kang, EM; Kim, BS; Kim, HJ; Kim, JH; Kim, TG; Lee, BU; Lee, HJ; Lim, BH; Nam, SH; Roh, YH; Seo, JW | 1 |
| Chang, HR; Chung, DU; Faull, KF; He, J; Saxton, RE; Shen, D; Whitelegge, JP | 1 |
| Hanada, R; Imai, K; Kikuchi, A; Mizutani, S; Mochizuki, S; Morio, T; Nonoyama, S; Ohara, O; Sato, M; Takahashi, N; Uchisaka, N; Watanabe, F | 1 |
| Asano, K; Iketani, O; Inamoto, H; Ishizaka, A; Kamata, H; Nakatani, M; Shirahata, T; Soejima, K; Tanigawara, Y; Yamayoshi, Y | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Kimura, T; Nishiyama, Y; Ohkawa, M; Takashima, H; Togami, T | 1 |
| Hida, T; Kimura, T; Saga, K | 1 |
| Bond, VK; Im, DD; Matsuo, K; Rosenshein, NB | 1 |
| Candeloro, G; Di Orio, F; Guerriero, G; Piazze, J; Rea, S; Recchia, F | 1 |
| Fang, Q; Ou, W; Sun, HB; Wang, SY; Yang, H; Zhang, BB | 1 |
| Cullen, KJ; Goloubeva, O; Haddad, RI; Nikitakis, N; Posner, MR; Sarlis, NJ; Schumaker, L; Tan, M | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Hou, XH; Jiang, L; Tang, LF; Wang, DF; Wang, DY; Xie, Z; Zhao, HD; Zhu, ZH | 1 |
| Fujii, A; Hayashi, A; Hidaka, D; Hiyama, J; Ikeda, K; Koshizuka, H; Misumi, Y; Miyagawa, Y; Nakanishi, K; Nakatsubo, S; Omagari, J; Sanada, H; Sawamoto, R; Tomimitsu, S; Tsuru, M | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Dangsuwan, P; Manchana, T | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Awad, M; Dakhil, S; Harbison, CT; Hart, LL; Hermann, RC; Horak, CE; Khambata-Ford, S; Lynch, TJ; Weber, MR; Xu, LA | 1 |
| Dakhil, S; Dreisbach, L; Gorton, S; Heim, WJ; Hermann, RC; Iannotti, NO; Lynch, TJ; McCleod, M; Paschold, E; Patel, T; Pautret, V; Weber, MR; Woytowitz, D | 1 |
| Chang, CS; Chang, TH; Lin, JT; Shih, SC | 1 |
| Chen, QY; Guo, X; Hong, MH; Lu, X; Xiang, YQ; Zeng, Q | 1 |
| Bamias, A; Bobos, M; Christodoulou, Ch; Dimopoulos, MA; Fountzilas, G; Karina, M; Kostopoulos, I; Papakostas, P; Pectasides, D; Pentheroudakis, G; Samantas, E; Vourli, G | 1 |
| Birnbaum, A; DiPetrillo, T; Kennedy, T; Rathore, B; Rathore, R; Ready, N | 1 |
| Imanaka, Y; Ishizaki, T; Sekimoto, M; Shirai, T | 1 |
| Corn, BW; Geva, R | 1 |
| Huang, XE; Jiang, W; Li, C; Lin, Y; Shi, MQ; Shu, YQ; Sunh, WL; Ye, Z; Zhang, Q; Zhou, JN | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Fossella, FV; Gladish, G; Hong, WK; Kies, MS; Kim, ES; Lee, JJ; Lippman, SM; Liu, DD; Tse, WH; William, WN | 1 |
| Fenner, M; Ganser, A; Grünwald, V; Ivanyi, P; Morgan, MA; Reuter, CW | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Braun, M; Büttner, R; Friedrichs, N; Höller, T; Kübler, K; Kuhn, W; Mielich, M; Pölcher, M; Rudlowski, C; Wolfgarten, M | 1 |
| Braun, M; Büttner, R; Fimmers, R; Friedrichs, N; Keyver-Paik, MD; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Sauerwald, A | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Niculescu-Duvaz, I | 1 |
| Andersson, K; Hillerdal, G; Sederholm, C | 1 |
| Allison, MA; Chang, HR; Chung, DU; Elashoff, R; Glaspy, J; Gornbein, J; Kass, FC | 1 |
| Chitapanarux, I; Lorvidhaya, V; Mayurasakorn, S; Pattarasakulchai, T; Sittitrai, P; Srivanitchapoom, C; Tananuwat, R; Tharavichitkul, E | 1 |
| Cheng, YC; Devata, S; Singh, V | 1 |
| Pagani, M | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N | 1 |
| Anders, C; Bran, G; Faber, A; Hörmann, K; Sadick, H; Sauter, A; Schultz, JD | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Fink, M | 1 |
| Gemma, A; Inage, S; Ise, Y; Katayama, S; Obayashi, M | 1 |
| Agelaki, S; Agelidou, A; Georgoulias, V; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Pallis, AG; Pavlakou, G; Syrigos, K; Varthalitis, I | 1 |
| Buyse, M; Crown, J; Eiermann, W; Forbes, J; Fumoleau, P; Jagiello-Gruszfeld, A; Mackey, JR; Martin, M; Mrsic-Krmpotic, Z; Pegram, MD; Pienkowski, T; Press, MF; Riva, A; Roche, H; Rolski, J; Sauter, G; Slamon, DJ; Taupin, H; Valero, V; von Minckwitz, G | 1 |
| Delle, U; Horvath, G; Levan, K; Olsson, B; Osterberg, L; Partheen, K; Sundfeldt, K | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Amm, H; Bevis, KS; Buchsbaum, DJ; Della Manna, D; Londoño Joshi, A; McNally, LR; Sellers, JC; Straughn, JM | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Argenta, PA; Boente, MP; Carson, LF; Downs, LS; Dusenbery, K; Geller, MA; Ghebre, R; Ivy, JJ; Jonson, AL; Judson, PL; Vogel, RI | 1 |
| Hillemanns, P; Kramer, F; Park-Simon, TW; Rinnau, F; Schippert, C | 1 |
| Duman, BB; Ercolak, V; Günaldi, M; Kara, IO | 1 |
| Devlin, PM; Haddad, RI; Holupka, EJ; Posner, MR; Sarlis, NJ; Sher, DJ; Tishler, RB | 1 |
| Amant, F; Beijnen, J; Calsteren, KV; Chai, DC; de Bruijn, E; De Catte, L; de Hoon, J; Demarsin, S; Devlieger, R; Heyns, L; Van Bree, R; Verbesselt, R | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Beck, SL; Cohen, JA; Lavoie Smith, EM; Pett, MA | 1 |
| Fujiwara, K; Kigawa, J; Kitada, F; Nagao, S; Nishimura, R; Takekida, S; Terakawa, N; Yamaguchi, S; Yoshida, N | 1 |
| Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Antimonik, NIu; Beliak, NP; Manikhas, GM | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA | 1 |
| Ichikawa, A; Kato, S; Kazumoto, T; Kudo, S; Kurimoto, F; Saito, Y; Saitoh, J; Sakai, H; Shibuya, K; Yoshida, D | 1 |
| Fauci, JM; Frederick, PJ; Kilgore, LC; Schneider, KE; Straughn, JM; Subramaniam, A; Whitworth, JM; Zhang, B | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H; Yuasa, T | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Das, M; Donington, JS; Eclov, N; Hoang, CD; Kozak, M; Le, QT; Loo, BW; Murphy, J; Wakelee, H; Whyte, RI; Zhou, L | 1 |
| Barraclough, H; Pavlakis, N; Standfield, L; Van Kooten, M; Weston, AR | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Honda, K; Imaishi, H; Kamura, T; Takemoto, S; Terada, A; Ushijima, K; Wada, H | 1 |
| Joshi, S; Khatri, A; Nair, S; Russell, PJ; Singh, PP | 1 |
| Dohi, S; Inoue, M; Kyo, S; Ohno, S; Ohno, Y; Soma, G; Sugiyama, H; Takakura, M | 1 |
| Crane, K | 1 |
| Fink, T; Fischer, JR; Griesinger, F; Marseille, A; Salm, T; Wolf, M | 1 |
| Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L | 1 |
| Bergmann, ZP; Debus, J; Freier, K; Jensen, AD; Krauss, J; Münter, MW; Weichert, W | 1 |
| Havrilesky, LJ; Higgins, RV; Holloway, RW; Kohler, MF; Lewandowski, GS; Nycum, LR; Pokrzywinski, R; Puls, LE; Revicki, DA; Secord, AA | 1 |
| Bayraktar, S; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Kuerer, HM; Lei, X; Melhem-Bertrandt, A; Meric-Bernstam, F; Sahin, AA; Valero, V | 1 |
| Coudillo-Luna, I; Novoa-Vargas, A; Sánchez-Bautista, K | 1 |
| Biesma, B; Dalesio, O; Groen, HJ; Hiltermann, TJ; Hochstenbag, MM; Schramel, FM; Sietsma, H; Smit, HJ; Termeer, A; van den Berg, A; van den Borne, BE; van Putten, JW; Vincent, A | 1 |
| Arichi, N; Hiraoka, T; Honda, S; Igawa, M; Mitsui, Y; Shiina, H; Yasumoto, H | 1 |
| Barraclough, H; Ganju, V; Kim, JH; Lee, DH; Magallanes, M; Martínez-Barrera, L; Orlando, M; Rodrigues-Pereira, J; van Kooten, M; Wang, J | 1 |
| Buhr, HJ; Fusi, A; Hotz, B; Hotz, HG; Keilholz, U | 1 |
| Deuss, B; Dickgreber, N; Nagel, S; Pabst, S; Roscher, K; Salm, T; Schuette, W; Schumann, C; von Weikersthal, LF | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Alvarez Secord, A; Berchuck, A; Havrilesky, LJ; Higgins, RV; Holloway, RW; Kohler, MF; Lewandowski, GS; Nycum, LR; Puls, LE; Valea, FA | 1 |
| Rose, PG | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Bangshöj, R; Boman, K; Graflund, M; Horvath, G; Lood, M; Malmström, H; Nygren, L; Sorbe, B; Swahn, M | 1 |
| Harbeck, N | 1 |
| Aoyagi, H; Asano, K; Matsuzaki, T; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Bangshöj, R; Boman, K; Graflund, M; Horvath, G; Lood, M; Malmström, H; Sorbe, B; Swahn, M | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Jin, F; Li, B; Li, Y; Lv, M; Mao, X; Yao, F | 1 |
| Gold, MA; Puls, LE; Scribner, DR | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Barnett, JC; Cohn, DE; Garfield, CF; Havrilesky, LJ | 1 |
| Cao, Y; Ge, QD; Liu, P; Lv, N; Tang, J; Wang, X; Wei, WD; Xiao, XS; Xie, XM; Xie, ZM | 1 |
| Brufsky, AM; Jankowitz, RC | 1 |
| Baselga, J; Bombonati, A; Rafferty, EA; Smith, BL | 1 |
| Fukuoka, M; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Mitsudomi, T; Nishimura, Y; Saka, H; Senba, H; Tada, H | 1 |
| Ellemann, AC; Kofoed, SC; Lundsgaard, M; Svendsen, LB | 1 |
| de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM | 1 |
| Crown, J; Gullo, G; Santoro, A; Sclafani, F; Zuradelli, M | 1 |
| Alexis, M; Awonuga, AO; Belotte, J; Bolinjkar, R; Deppe, G; Tabassum, F | 1 |
| Asano, A; Hirasawa, N; Horikawa, Y; Ishihara, S; Itoh, Y; Koyama, K; Murao, T; Naganawa, S; Nomoto, Y; Obata, Y; Sasaoka, M; Suzuki, K | 1 |
| Coyle, C; Dyker, KE; Karakaya, E; Oksuz, DC; Prestwich, RJ; Sen, M; Yetmen, O | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Allred, JB; Apsey, H; Mattar, B; Nikcevich, D; Northfelt, DW; Perez, EA; Pockaj, BA; Roy, V | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Barnett, F; Stewart, J; Turner, N; White, S | 1 |
| Hata, Y; Homma, S; Isobe, K; Mitsuda, A; Sakaguchi, S; Sakamoto, S; Sano, G; Sato, F; Sato, K; Shibuya, K; Sugino, K; Takagi, K; Takahashi, S; Takai, Y; Terahara, A | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P | 1 |
| Li, K; Li, W | 1 |
| Agarwal, A; Cooley, TP; Logeswaran, P; Mehta, A; Subramaniam, RM | 1 |
| Bell, R; Khasraw, M | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Fietkau, R; Iro, H; Kuwert, T; Lell, M; Lettmaier, S; Schmidt, D; Semrau, S; Waldfahrer, F | 1 |
| Che, L; Di, L; Jia, J; Jiang, H; Liang, X; Lyerly, HK; Ren, J; Song, G; Wan, F; Wang, X; Yan, Y; Yu, J; Zhang, J; Zhou, X; Zhu, Y | 1 |
| Durdux, C; Huguet, F; Lang, P; Monnier, L; St Guily, JL; Touboul, E | 1 |
| Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, HR; Kim, SB; Kim, SI; Lee, KH; Lee, S; Park, KH; Sohn, JH | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
| Aihara, S; Hashiguchi, M; Iwasaka, T; Nakao, Y; Nishiyama, S; Noguchi, M; Yasunaga, M; Yokoyama, M | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Cao, X; Feng, Y; Huang, H; Huang, X; Huang, Y; Lan, C; Liu, J | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Gomez-Fernandez, C; Hurley, J; Larrieu, R; Leone, JP; Pegram, MD; Reis, IM; Rodgers, SE; Wright, J | 1 |
| Abramson, VG; Beckermann, KE; Iams, W; Mayer, IA; Neff, AT | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Andreu, F; Arellano, A; Arnaiz, Mdel M; Calvo, F; Cardenal, F; Cobo, M; Delgado, R; Dómine, M; García-Gómez, R; Garrido, P; Isla, D; Massutí, B; Morán, T; Morera, R; Perez-Casas, A; Ramos, A; Rosell, R; Valencia, J; Zamora, J | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Cortes Vizcaino, V; Gil Salom, M; Moratalla Charcos, LM; Osca Garcia, JM; Pastor Navarro, T | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Chia, S; Cortés, J; Eniu, A; Harvey, V; Hegg, R; Hickish, T; McNally, V; Ratnayake, J; Ross, G; Schneeweiss, A; Seo, JH; Tausch, C; Tsai, YF | 1 |
| Akino, H; Aoki, Y; Ishida, H; Ito, H; Kusukawa, N; Ooyama, N; Tanase, K; Yokoyama, O | 1 |
| Darwiche, K; Freitag, L; Goldberg, EP; Huang, H; Li, Q; Petridis, D; Ritzoulis, C; Spyratos, D; Yarmus, L; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Derks, J; Dingemans, AM; Heideman, DA; Mellema, WW; Smit, EF; Snijders, PJ; Thunnissen, E; Van Suylen, R | 1 |
| Chida, K; Inui, N; Karayama, M; Kuroishi, S; Masuda, M; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Au, HJ; Bée, V; Chan, A; Crown, J; Eiermann, W; Ferrero, JM; Fornander, T; Glaspy, J; Lalla, D; Liu, MC; Mackey, J; Martin, M; Miller, DP; Pawlicki, M; Pienkowski, T; Pintér, T; Robert, NJ; Santana, MJ; Sehdev, S; Slamon, DJ | 1 |
| Alvarez, RD; Anwer, K; Chu, C; Fewell, JG; Kelly, FJ; Lewis, D | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
| Kolek, V | 1 |
| Stinchcombe, TE | 1 |
| Chen, L; Feldman, LE; Garnett, A; Herman, LC; Smith, B; Spiotto, MT; Weichselbaum, RR | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Asami, K; Atagi, S; Fujita, Y; Fukuoka, K; Kawahara, M; Kawasaki, M; Komuta, K; Kubota, K; Minato, K; Nogami, N; Ogushi, F; Shibata, K; Tomizawa, Y; Tsuchiya, M; Yamanaka, T; Yonei, T; Yoshioka, H | 1 |
| Candon, D; Crown, J; Healy, J | 1 |
| Barraclough, H; Cheng, R; Kim, JH; Orlando, M; Pereira, JR | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Gemma, A; Harada, T; Inoue, A; Ishimoto, O; Kambe, M; Maemondo, M; Minegishi, Y; Miwa, K; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Ube, K; Usui, K; Watanabe, K | 1 |
| Kalisch, A; Kern, P; Kimmig, R; Kolberg, HC; Kurbacher, C; Otterbach, F; Pott, D; Sikov, WM; von Minckwitz, G | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A | 1 |
| Lin, GN; Liu, DY; Peng, JW; Xia, ZJ; Xiao, JJ | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Bacakoglu, F; Cok, G; Erdinc, M; Goker, E; Goksel, O; Goksel, T; Karakus, H; Uslu, R | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Cheng, J; Jin, C; Liu, X; Liu, Y; Qi, X; Yang, J; Yu, D; Zhao, X | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Ando, M; Gemma, A; Hino, M; Iwasawa, S; Minato, K; Miura, Y; Noro, R; Okamoto, H; Shingyoji, M; Takiguchi, Y; Yoshimori, K | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Eppler, S; Gordon, M; Lum, BL; Redfern, CH; Trudeau, C; Xu, N | 1 |
| Li, X; Li, Y | 1 |
| Agüero, A; Farré, N; García, J; León, X; López, M; López-Pousa, A; Quer, M | 1 |
| DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y | 1 |
| Annede, P; Bauduceau, O; Bosacki, C; Ceccaldi, B; Chargari, C; Dulou, R; Falk, AT; Ferrand, FR; Guy, JB; Helissey, C; Jacob, J; Langrand-Escure, J; Le Moulec, S; Magné, N; Mbagui, R; Mery, B; Vedrine, L | 1 |
| Gilbar, P; McPherson, I; Sorour, N | 1 |
| Izzo, C | 1 |
| Autret, D; Capitain, O; Cellier, P; El Alouani, C; Gustin, P; Jadaud, É; Laccourreye, L; Peyraga, G; Pointreau, Y; Septans, AL; Tuchais, C; Vinchon-Petit, S; Yossi, S | 1 |
| Eppler, S; Gordon, MS; Han, K; Lum, BL; Redfern, CH; Trudeau, C; Xu, N | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Liu, D; Qian, J; Su, B; Xu, W; Zhang, J; Zhang, ZW; Zheng, H | 1 |
| Ahn, JB; Choi, HJ; Chung, HC; Heo, SJ; Jung, M; Kim, HR; Kim, HS; Lee, CK; Rha, SY; Roh, MR; Shin, SJ | 1 |
| Fukuda, S; Furusawa, J; Hatakeyama, H; Homma, A; Kano, S; Mizumachi, T; Nakamaru, Y; Onimaru, R; Sakashita, T; Shirato, H; Terasaka, S; Tsuchiya, K; Yasuda, K; Yoshida, D | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Dank, M; Györke, T; Kajáry, K; Kulka, J; Lengyel, Z; Molnár, BÁ; Szentmártoni, G; Tőkés, AM; Tőkés, T; Torgyík, L | 1 |
| Dang, Y; Fan, F; Gao, Y; Geng, J; Jia, H; Li, E; Li, M; Ma, X; Shang, L; Song, Y; Ti, X; Xue, X; Zhang, K; Zhang, W; Zhang, Y; Zhou, W | 1 |
| Breheret, R; Capitain, O; Laccourreye, L; Linot, B; Peyraga, G; Yossi, S | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Abdel-Aziz, NM; Abozeed, WN; Alsaleh, K; Alzahrani, A; Elbiomy, MA; Elsamany, S; Farooq, MU; Rasmy, A; Rawah, E | 1 |
| Fujiwara, K; Hasegawa, T; Hasumi, Y; Kigawa, J; Matsumoto, T; Nagao, S; Nakamura, K; Nishio, S; Okada, S; Otsuki, T; Shimada, M; Suzuki, M; Takano, M; Takei, Y; Takekuma, M; Tanabe, H | 1 |
| Liu, E; Liu, Z; Zhou, Y | 1 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Arts, H; de Munck, L; de Vries, E; Hollema, H; Hospers, G; Reyners, A; Timmer-Bosscha, H; van der Marel, P; van Kruchten, M | 1 |
| Ikuta, S; Inoue, K; Sonoda, T; Tani, S; Tsubamoto, H; Yamanaka, N | 1 |
| Arichi, N; Harada, Y; Hiraki, M; Mitsui, Y; Shiina, H; Yasumoto, H | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Brown, R; Glass, S; He, YJ; Hoskins, JM; McLeod, HL; Motsinger-Reif, A; Paul, J; Winham, SJ | 1 |
| Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C | 1 |
| Kalisch, A; Kern, P; Kimmig, R; Kolberg, HC; Kurbacher, C; Pott, D; Pütter, C; Rezai, M; von Minckwitz, G | 1 |
| Berg, S; Boessert, P; Fruth, K; Haxel, BR; Mann, WJ | 1 |
| Cui, Y; Huang, C; Qi, D; Qi, XA; Tian, Y; Wang, Q; Xin, L; Xu, J; Yang, Y | 1 |
| Ball, DW; Busaidy, NL; Byrd, D; Callender, G; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, JC; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Smallridge, RC; Sturgeon, C; Wang, TN; Wirth, LJ | 1 |
| Dickow, B; Fontana, J; Heath, E; Heilbrun, L; Land, S; Li, J; Shevrin, D; Smith, D; Stark, K; Stein, M; Vaishampayan, U | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Arya, S; Bhattacharjee, A; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Kane, S; Muddu, V; Noronha, V; Patil, VM; Prabhash, K | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Chen, L; Guo, R; Li, WF; Lin, AH; Liu, X; Ma, J; Sun, Y; Zhang, F; Zhang, Y | 1 |
| Boyd, T; Cheng, HH; Montgomery, B; Nelson, PS; Pritchard, CC | 1 |
| Gridelli, C; Sacco, PC | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W | 1 |
| Cho, BC; Heo, SJ; Jeong, J; Jung, I; Kim, HR; Kim, JH; Lee, CK; Lim, SM; Moon, YW; Shim, HS | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Guo, B; Lannér, C; Masilamani, T; Mispel-Beyer, K; Narendrula, R; Parissenti, AM; Pritzker, K; Pritzker, LB; Wang, X | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T | 1 |
| Del Monte-Millán, M; Fuentes, H; García-Saenz, JA; Gómez, H; González-Rivera, M; Jerez, Y; Lobo, M; López-Tarruella, S; Márquez-Rodas, I; Martin, M; Massarrah, T; Moreno, F; Ocaña, I; Pérez-Carbornero, L; Picornell, A; Ramos-Medina, R; Santillán Garzón, S | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Alvarez, RD; Becker, DA; Bevis, KS; Boone, JD; Gilbert, AL; Huh, WK; Leath, CA; Straughn, JM; Thomas, ED | 1 |
| Ameri, A; Khoshbakht Ahmadi, H; Mortazavi, N; Novin, K | 1 |
| Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O | 1 |
| Chen, K; Chen, Y; Gong, C; Nie, Y; Qu, S; Song, E; Su, F; Xiao, X | 1 |
| Amin, AL; Barnadas, A; Bretel Morales, D; Connor, CS; Cortes, J; Del Monte-Millán, M; Fabian, CJ; Fuentes Rivera, H; García-Saenz, JA; Godwin, AK; Gómez, HL; González Del Val, R; Gonzalez-Rivera, M; Heldstab, J; Jensen, RA; Jerez-Gilarranz, Y; Khan, QJ; Kimler, BF; Klemp, JR; López-Tarruella, S; Mammen, JM; Márquez-Rodas, I; Martin, M; Massarrah, T; McGinness, MK; Moreno, F; Palomero, MI; Pelaez-Lorenzo, B; Perou, CM; Picornell, AC; Prat, A; Sharma, P; Wagner, JL; Ward, C | 1 |
| Abraham, J; Budd, GT; Calhoun, B; Fanning, A; Grobmyer, SR; Mishra, P; Montero, AJ; Moore, H; Raska, P; Stewart, R; Tiwari, SR; Valente, S | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Fujiwara, K; Kigawa, J; Nagao, S; Nishimura, R; Shimada, M; Shoji, T; Sugiyama, T; Takeshima, N; Takizawa, K; Yamaguchi, S | 1 |
| Adam, JP; Gauthier, P; Letarte, N | 1 |
| Kamimura, K; Matsumoto, Y; Moriyama, M; Saijo, Y; Zhou, Q | 1 |
| Liu, CC; Lu, Y; Tang, H; Wang, H; Zhu, J | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Gao, JJ; Pohlmann, PR; Swain, SM; Tan, M | 1 |
| Alfieri, S; Bergamini, C; Bossi, P; Cavallo, A; Cova, A; Granata, R; Huber, V; Iacovelli, NA; Imbimbo, M; Licitra, L; Locati, L; Mariani, L; Miceli, R; Orlandi, E; Resteghini, C; Rivoltini, L | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Afors, K; Akladios, C; Baldauf, JJ; Hummel, M; Kurtz, JE; Lecointre, L; Marchal, F; Mathelin, C; Petit, T; Rebstock, LE; Schrot-Sanyan, S | 1 |
| Chubb, LS; Gustafson, DL; Hansen, RJ; Wittenburg, LA; Worley, DR | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Bueno, C; Del Monte-Millan, M; Echavarria, I; García-Saenz, JA; Granja, M; Jerez, Y; Lobo, M; Lopez-Tarruella, S; Marquez-Rodas, I; Martín, M; Moreno, F; Peinado, P; Sotelo, M; Torres, G | 1 |
| Behera, D; Sharma, S; Singh, A; Singh, N | 2 |
| Christensen, IJ; Ekmann-Gade, AW; Hansen, A; Høgdall, C; Høgdall, E; Jensen, PB; Jensen, T; Karlsen, MA; Knudsen, S; Mirza, MR; Nedergaard, L; Novotny, GW; Prahm, KP | 1 |
| Han, B; He, L; Li, Y; Yuan, J | 1 |
| Go, T; Liu, D; Matsuura, N; Nakano, J; Nakano, T; Nakashima, N; Nii, K; Tarumi, S; Tokunaga, Y; Yokomise, H | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Fujiuchi, N; Hasebe, T; Hirokawa, E; Matsuura, K; Misumi, M; Osaki, A; Saeki, T; Sakurai, T; Shigekawa, T; Shimada, H; Sugitani, I; Takahashi, T; Takeuchi, H; Ueda, S | 1 |
| Albers, AE; Fichtner, I; Hoffmann, J; Keilholz, U; Klinghammer, K; Leser, U; Otto, R; Raguse, JD; Tinhofer, I | 1 |
| Allende, D; Fadare, O; Forscher, C; Roma, AA; Rutgers, JK | 1 |
| Carey, LA; Dusetzina, SB; Hinton, SP; Meng, K; Meyer, AM; Reeder-Hayes, KE | 1 |
| Breathnach, O; Carr, A; Crown, J; Duke, D; Eustace, AJ; Fay, J; Gallagher, W; Grogan, L; Gullo, G; Hambly, N; Hennessy, BT; Hill, AD; Kay, EW; Kelly, C; Kennedy, MJ; Madden, SF; Milewska, M; Moulton, B; O'Donovan, N; Power, C; Sheehan, KM; Teiserskiene, A; Toomey, S; Walshe, J | 1 |
| Kai, M; Kubo, M; Nakamura, M; Yamada, M; Yamamoto, H | 1 |
| Binder, PS; Cusworth, S; Divine, LM; Hagemann, AR; Kuroki, LM; Massad, LS; McCourt, CK; Mutch, DG; Powell, MA; Thaker, PH; Zhao, P | 1 |
| DeLuca, AN; Esserman, LJ; Melisko, ME; Rice, BA; Rugo, HS; Ver Hoeve, ES | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Afenjar, K; Beckmann, MW; Boileau, JF; Campone, M; Fresco, R; Harbeck, N; Helms, HJ; Huang, CS; Hurvitz, SA; Jung, KH; Lin, YG; Martin, M; Slamon, D; Sparano, J; Stroyakovskiy, D; Symmans, WF; Thompson, AM; Valero, V; Wildiers, H; Xu, J | 1 |
| Aviñó, V; Bayo, J; Jiménez, F; Toscano, F | 1 |
| Kigawa, J; Kiyokawa, T; Kojima, A; Mikami, Y; Nagao, S; Nishimura, R; Shimada, M; Sugiyama, T; Takeshima, N; Teramoto, N | 1 |
| Borel, C; Burgy, M; Leblanc, J | 1 |
| Han, SM; Kong, TH; Seo, YJ | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Burki, TK | 1 |
| Isaka, K; Kato, R; Nakayama, D; Nishi, H; Sagawa, Y; Terauchi, F | 1 |
| Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Sakazaki, Y; Tokito, T; Tsuneyoshi, S; Yamada, K; Zaizen, Y | 1 |
| Azim, HA; Kassem, L; Lasheen, S | 1 |
| Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
| Amin, AL; Barnadas, A; Cortés, J; Fuentes-Rivera, H; García-Saenz, JA; Godwin, AK; Gómez, HL; González Del Val, R; González-Rivera, M; Heldstab, J; Jensen, RA; Jerez-Gilarranz, Y; Khan, QJ; Kimler, BF; Klemp, JR; Lehn, C; López-Tarruella, S; Mammen, JV; Márquez-Rodas, I; Martín, M; Massarrah, T; Monte-Millán, MD; Morales, DB; Moreno, F; O'Dea, AP; Palomero, MI; Pelaez-Lorenzo, B; Perou, CM; Picornell, AC; Prat, A; Sharma, P; Wagner, JL; Wang, YY | 1 |
| Carr, A; Coté, D; Cremona, M; Crown, J; Eustace, A; Fay, J; Furney, S; Hennessy, B; Kay, E; Kennedy, S; Madden, S; Milewska, M; Toomey, S | 1 |
| Wu, HL | 1 |
| Huang, Q; Jiang, Y; Li, Q; Li, S; Liu, J; Wei, W; Yang, H | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Begier-Krasińska, B; Książek, K; Mikuła-Pietrasik, J; Niklas, A; Pakuła, M; Tykarski, A; Uruski, P; Witucka, A | 1 |
| Albrecht, TL; Beebe-Dimmer, JL; Greenwald, MK; Ruterbusch, JJ; Schwartz, AG; Simon, MS | 1 |
| Daido, W; Funaishi, K; Hattori, N; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Blumenschein, GR; Garden, AS; Ginsberg, LE; Glisson, BS; Gold, KA; Haddad, RI; Hutcheson, K; Johnson, FM; Kies, MS; Lee, JJ; Lewis, J; Lin, HY; Massarelli, E; Myers, J; Papadimitrakopoulou, V; Pharaon, RR; Pickering, C; Rabinowits, G; Tishler, RB; William, WN; Williams, MD | 1 |
| Killock, D | 1 |
| Iwami, E; Kuroda, A; Matsuzaki, T; Nakajima, T; Sasahara, K; Terashima, T | 1 |
| Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
| Bauer, TM; Faessel, H; Faller, DV; Harvey, RD; Lockhart, AC; Nemunaitis, J; Sedarati, F; Venkatakrishnan, K; Zhou, X | 1 |
| Afenjar, K; Boileau, JF; Boulet, T; Campone, M; Fasching, PA; Harbeck, N; Huang, CS; Hurvitz, SA; Jung, KH; Lopez-Valverde, V; Martin, M; Slamon, D; Song, C; Sparano, JA; Spera, G; Stroyakovskiy, D; Symmans, WF; Thompson, AM; Trask, P; Valero, V; Wildiers, H | 1 |
| Beith, J; Boyle, FM; Chen, TYT; Currow, DC; Della-Fiorentina, SA; Johnston, A; Lin, E; Moylan, EJ; Tervonen, HE | 1 |
| Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y | 1 |
| Bourlon, MT; Gabutti, A; Remolina-Bonilla, YA; Saldivar-Oviedo, B; Trejo-Rosales, RR | 1 |
| Anazodo, A; Dickinson, JE; Li, Z; Lui, K; Safi, N; Sullivan, EA; Wang, AY | 1 |
| Ángeles-Bueno, WG; Díaz-Sifuentes, JM; Mendoza-Medina, DF; Mendoza-Sánchez, F; Montes-López, GA; Pérez-Landeros, JE | 1 |
| Aoki, D; Arai, M; Mizuno, M; Nakai, H; Nakanishi, T; Nishio, S; Nomura, H; Susumu, N; Takehara, K; Tokunaga, H; Watanabe, Y; Yaegashi, N; Yokoyama, Y | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Chung, S; Cooper, J; Dadwal, S; Jung, J; Kruper, L; Mortimer, JE; Stewart, D; Wong, L; Yu, KW; Yuan, Y | 1 |
| Aggarwal, R; Bok, RA; Carvajal, L; Chen, HY; Gordon, JW; Kurhanewicz, J; Larson, PEZ; Lee, P; Ohliger, MA; Slater, JB; Small, EJ; van Criekinge, M; Vigneron, DB; Zhu, Z | 1 |
| Cui, M; Cui, S; Jia, Y; Jia, Z; Li, Z; Wang, L; Xu, T | 1 |
| Agaimy, A; Fietkau, R; Haderlein, M; Hecht, M; Iro, H; Kitzsteiner, C; Kuwert, T; Müller, S; Schmidt, D; Semrau, S; Traxdorf, M | 1 |
| Awan, A; Basulaiman, B; Bedard, D; Brunet, MC; Clemons, M; Fergusson, D; Hutton, B; Kehoe, A; MacDonald, F; Mallick, R; Mazzarello, S; Robinson, A; Saunders, D; Stober, C; Vandermeer, L | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Liang, MR; Liu, H; Wang, YN; Zeng, SY; Zhong, ML | 1 |
| Ando, M; Atagi, S; Azuma, K; Fujita, Y; Horiike, A; Horinouchi, H; Hosomi, Y; Murakami, H; Nakagawa, K; Niho, S; Nokihara, H; Nomura, S; Ohe, Y; Okamoto, H; Okamoto, I; Ozaki, T; Sugawara, S; Yamamoto, N; Yoneshima, Y | 1 |
| Burstein, HJ; Hassett, MJ; Li, H; Punglia, RS | 1 |
| Sidaway, P | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
| Adnet, J; Bertaut, A; Coudert, B; Favier, L; Foucher, P; Kaderbhaï, CG; Lagrange, A; Martin, E; Mettey, L; Peignaux-Casasnovas, K; Tharin, Z | 1 |
| Fan, WL; Li, JZ; Pu, CL | 1 |
| Bueno, C; Carolla, RL; Chen, B; Hillman, DW; Jenkins, RB; Johnson, DB; Leon-Ferre, RA; Moreno-Aspitia, A; Northfelt, DW; Perez, AT; Perez, EA; Zon, RT | 1 |
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Lambertini, M; Perachino, M; Poggio, F | 1 |
| Hamauchi, S; Kawakami, T; Mori, K; Ogawa, H; Onitsuka, T; Onoe, T; Onozawa, Y; Shirasu, H; Yokota, T | 1 |
| Cheng, MY; Gao, HF; Hu, MX; Ji, F; Li, WP; Wang, K; Xu, FP; Yang, CQ; Yang, M; Zhang, LL; Zhu, T | 1 |
| Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
| Coe, F; Ekholm, M; Horsley, L; Howell, SJ; Wang, X | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Choi, JH; Jeon, CW; Jung, S; Kim, YO | 1 |
| Aggarwal, RR; Alva, AS; Borno, HT; Chi, KN; Chou, J; Desai, A; Dhawan, MS; Feng, FY; Koshkin, VS; Kwon, DH; Reimers, MA; Small, EJ; Wright, F; Wyatt, AW; Yip, SM; Zhang, L | 1 |
| Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW | 1 |
| Alvarez, E; Asensio, F; Bernat, R; Bueno, O; Cebollero, M; Del Monte-Millan, M; Echavarria, I; García-Saenz, JA; Gonzalez Del Val, R; Gonzalez-Haba, E; Herrero, B; Jerez, Y; Lizarraga, S; Lobato, N; Lopez-Tarruella, S; Marquez-Rodas, I; Martin, M; Massarrah, T; Moreno, F; Palomero, MI; Ramos-Medina, R; Rincon, P; Romero, P | 1 |
| Kigawa, J; Nagao, S; Nakamura, K; Sato, S; Shimada, M; Shoji, T; Sueoka, K; Takehara, K; Tokunaga, H; Yamaguchi, S | 1 |
| Damghani, MA; Larizadeh, MH; Mohammadi, F; Shabani, M | 1 |
| Ademuyiwa, FO; Akintola-Ogunremi, O; Anurag, M; Bagegni, N; Basu, A; Bose, R; Chen, I; Church, SE; Clifton, K; Davis, J; Ellis, MJ; Ferrando-Martinez, S; Fisk, B; Frith, A; Gao, F; Gillanders, W; Griffith, M; Griffith, OL; Hagemann, IS; Hernandez-Aya, LF; Jeffers, G; Lee, BH; Luo, J; Ma, CX; Opyrchal, M; Peterson, LL; Rearden, TP; Richters, M; Rigden, CE; Rimawi, MF; Roshal, A; Skidmore, ZL; Suresh, R; Weilbaecher, K | 1 |
| Bai, H; Han, Y; Niu, Y; Zhang, M | 1 |
| Bai, GC; He, ZS; Jin, J; Song, Y; Yu, W | 1 |
| Cao, Y; Cheng, MY; Gao, HF; Ji, F; Li, J; Lin, Y; Liu, Z; Wang, K; Wu, ZY; Yang, CQ; Yang, M; Zhang, G; Zhang, L; Zhu, T | 1 |
| Chang, DD; Feng, ST; Guo, QK; Lei, YY; Li, HJ; Liu, LZ; Xu, BC; Xu, M; Yan, J; Yao, W; Zhu, Y; Zhu, ZH | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Ahn, JS; Chae, BJ; Im, YH; Kim, JY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Park, YH; Ryu, JM; Yu, J | 1 |
| Chen, X; Liu, Z; Lu, Z; Qiao, J; Sun, X; Wang, C; Wang, H; Wang, Y; Xia, Q; Yan, M; Zhou, Y; Zhu, J | 1 |
| Berger, M; Collins, S; Le, D; Palettas, M; Vargo, C; Williams, N | 1 |
| Andrade, MF; Bowers, RR; Delaney, JR; Jones, CM; Voelkel-Johnson, C; White-Gilbertson, S | 1 |
| Ishizuka, M; Kaibori, M; Kosaka, H; Okamoto, Y; Sekimoto, M; Suganami, A; Sumiyama, F; Tamura, Y | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Guo, S; Li, S; Ma, K; Wang, J; Wei, S; Xu, Y; Zhang, F | 1 |
| Borisyuk, BO; Bororov, LV; Ganul, AV; Maliarchuk, K; Shevchenko, AI; Sovenko, VM | 1 |
| Igai, H; Kamiyoshihara, M; Matsuura, N; Numajiri, K; Ohsawa, F | 1 |
| Accetta, C; Carbognin, L; D'Angelo, T; Di Giorgio, D; Di Leone, A; Fabi, A; Franceschini, G; Fuso, P; Garganese, G; Giannarelli, D; Magno, S; Masetti, R; Muratore, M; Paris, I; Pavese, F; Sanchez, AM; Scambia, G; Terribile, DA; Tiberi, G | 1 |
| Kalabova, H; Melichar, B; Ondruskova, A; Purova, D; Rusarova, N; Studentova, H; Vitaskova, D | 1 |
| Kubota, K; Kunitoh, H; Maruyama, R; Matsuda, A; Ohira, T; Okamoto, H; Seto, T; Tsuboi, M; Yamaoka, K | 1 |
| Nakano, E; Namikawa, K; Ogata, D; Wada, S; Yamazaki, N | 1 |
| Ding, K; Ding, X; Ding, Y; Gu, X; He, X; Liang, C; Mo, W; Qin, C; Wang, O; Xie, X; Yang, H; Zhao, S | 1 |
| Bliss, J; Cheang, MCU; Gazinska, P; Grigoriadis, A; Haider, S; Hoadley, KA; Kennedy, RD; Kernaghan, S; Kilburn, L; Loi, S; Parker, JS; Perou, CM; Pinder, SE; Quist, J; Roxanis, I; Salgado, R; Sipos, O; Tovey, H; Tutt, A | 1 |
| Kanao, H; Koike, R; Kurihara, N; Nomura, H; Omatsu, K; Sekizawa, A; Yunokawa, M | 1 |
| Brufsky, AM; Ding, Y; Gomez Marti, JL; Nasrazadani, A; Normolle, D | 1 |
| Ahn, JS; Chae, BJ; Cho, WK; Im, YH; Kim, H; Kim, JY; Kim, N; Kim, SW; Kim, TG; Lee, JE; Lee, SK; Nam, SJ; Park, W; Park, YH; Ryu, JM; Yu, J | 1 |
83 review(s) available for docetaxel anhydrous and carboplatin
| Article | Year |
|---|---|
Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 1995 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Taxoids | 1997 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure | 1999 |
Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
New options in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 1999 |
Paclitaxel and docetaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
The platinum agents: a role in breast cancer treatment?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Body surface area as a determinant of pharmacokinetics and drug dosing.
Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Docetaxel and radiation as combined-modality therapy.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Taxanes for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
First-line chemotherapy for NSCLC: an overview of relevant trials.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival; Taxoids; Treatment Outcome | 2002 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Current status of taxane and platinum-based chemotherapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Education, Medical, Continuing; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Prognosis; Radiation Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Optimizing primary chemotherapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Docetaxel: an alternative taxane in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2003 |
[Docetaxel and ovarian cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2004 |
HERe-2 stay: the continuing importance of translational research in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Taxoids; Trastuzumab; Up-Regulation | 2004 |
[Docetaxel and non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2004 |
[Neurotoxic effects of medications: an update].
Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans; Interferon-alpha; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thalidomide | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
[Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Taxoids; Treatment Outcome | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2005 |
First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2005 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Catastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature).
Topics: Adenocarcinoma, Clear Cell; Adolescent; Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Carboplatin; Cerebral Hemorrhage; Cerebral Infarction; Docetaxel; Fatal Outcome; Female; Humans; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Palliative Care; Paraneoplastic Syndromes; Protein C Deficiency; Protein S Deficiency; Pulmonary Embolism; Taxoids; Thrombophilia; Thrombophlebitis; Warfarin | 2007 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
Quality-of-life issues in the management of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2007 |
Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies.
Topics: Animals; Antineoplastic Agents; Carboplatin; Docetaxel; Epothilones; Humans; Models, Animal; Neurotoxins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2008 |
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2008 |
First- and second-line therapy for advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Meta-Analysis as Topic; Palliative Care; Patient Selection; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
What is the role of novel taxanes in non-small-cell lung cancer?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cross-Linking Reagents; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2008 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Docetaxel; Female; Fluorouracil; Genes, erbB-2; Humans; Immunoconjugates; Maytansine; Mice; Mice, SCID; Receptor, ErbB-2; Taxoids; Trastuzumab | 2010 |
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Asparaginase; Carboplatin; Cisplatin; Cytostatic Agents; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Procarbazine; Risk Factors; Taxoids; Teniposide | 2010 |
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Mixed Tumor, Mullerian; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Salpingectomy; Taxoids; Tomography, X-Ray Computed | 2011 |
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Reproducibility of Results; Taxoids | 2011 |
[Malignant arrhenoblastoma. Case report and literature review].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Combined Modality Therapy; Diagnostic Imaging; Docetaxel; Female; Humans; Hysterectomy; Ovarian Neoplasms; Ovariectomy; Pleural Effusion, Malignant; Sertoli-Leydig Cell Tumor; Taxoids; Virilism | 2011 |
A case report of primary small cell carcinoma of the breast and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Small Cell; CD56 Antigen; Docetaxel; Female; Humans; Lymphatic Metastasis; Mammography; Nuclear Proteins; Phosphopyruvate Hydratase; Synaptophysin; Taxoids; Thyroid Nuclear Factor 1; Transcription Factors; Ultrasonography | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2015 |
Novel cytotoxic drugs in advanced nonsmall cell lung cancer.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Treatment Outcome | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm Grading; Peritoneal Neoplasms; Prognosis; Survival Rate; Taxoids; Thoracic Surgery, Video-Assisted | 2017 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2018 |
Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Physiological Phenomena; Cisplatin; Docetaxel; Female; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel | 2019 |
Use of synthetic stomata in abdominal carcinomatosis. Case report and literature review.
Topics: Adenocarcinoma, Papillary; Adult; Antineoplastic Combined Chemotherapy Protocols; Argon Plasma Coagulation; Bevacizumab; Carboplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Docetaxel; Doxorubicin; Drainage; Fatal Outcome; Female; Humans; Hyperthermia, Induced; Intestinal Neoplasms; Intestinal Perforation; Mitomycin; Ovarian Neoplasms; Polyethylene Glycols; Surgical Stomas | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
225 trial(s) available for docetaxel anhydrous and carboplatin
| Article | Year |
|---|---|
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Docetaxel; Drug Resistance; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Taxoids | 1994 |
The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors; Treatment Outcome | 1998 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Constipation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2001 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stomatitis; Taxoids | 2002 |
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Study shows 2-year survival advantage for docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2002 |
A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2002 |
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; White People | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Remission Induction; Taxoids; Treatment Outcome | 2003 |
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Estramustine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2004 |
A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status.
Topics: Adult; Aged; Carboplatin; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2004 |
Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2004 |
Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2005 |
Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Taxoids; Uterine Cervical Neoplasms | 2005 |
Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Docetaxel; Female; Humans; Male; Melphalan; Middle Aged; Taxoids | 2005 |
Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2005 |
[Results of docetaxel therapy in patients with relapsed ovarian cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids; Treatment Outcome | 2005 |
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Sulindac; Taxoids | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Salvage Therapy; Survival Rate; Taxoids | 2005 |
A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2006 |
A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Taxoids | 2006 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Italy; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Taxoids; Thailand | 2006 |
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Vinblastine | 2006 |
Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2006 |
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Radiotherapy Dosage; Remission Induction; Taxoids | 2006 |
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carnitine; Chromatography, High Pressure Liquid; Creatinine; Docetaxel; Female; Glucose; Humans; Infusions, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Phosphates; Taxoids; Urea; Vinblastine; Vinorelbine | 2007 |
Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2007 |
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2007 |
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; ROC Curve; Taxoids; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2006 |
Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2007 |
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Taxoids | 2007 |
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Taxoids | 2007 |
A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Treatment Outcome | 2007 |
Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Risk Factors; Survival Analysis; Taxoids | 2006 |
Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2007 |
[Phase I study of docetaxel combined with carboplatin in patients with non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Taxoids | 2006 |
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Survival Analysis; Taxoids | 2007 |
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mitomycin; Neoplasm Staging; Neoplasms, Squamous Cell; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous | 2007 |
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Chromogranin A; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2008 |
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Survival Analysis; Taxoids | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Greece; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Outpatients; Palliative Care; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligodeoxyribonucleotides; Paclitaxel; Taxoids; Toll-Like Receptor 9 | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Taxoids | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2009 |
Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Taxoids | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome | 2009 |
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Taxoids | 2009 |
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; United States; Zoledronic Acid | 2010 |
[rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endostatins; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Taxoids | 2009 |
Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Prospective Studies; Taxoids | 2009 |
A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Taxoids | 2010 |
Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.
Topics: Adult; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Middle Aged; Models, Biological; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Precision Medicine; Predictive Value of Tests; Prospective Studies; Proteomics; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Killer Cells, Natural; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes, Regulatory; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Taxoids | 2010 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Prognosis; Taxoids; Treatment Outcome; Tubulin | 2009 |
Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Erythrocyte Transfusion; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Taxoids; Young Adult | 2010 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal caricinoma: docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Survival Rate; Taxoids; Thrombocytopenia; Vomiting | 2010 |
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Diarrhea; Docetaxel; ErbB Receptors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Prognosis; Receptor, ErbB-2; Stomach Neoplasms; Taxoids; Tissue Array Analysis; Treatment Outcome | 2010 |
Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Head and Neck Neoplasms; Hospitals, University; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2010 |
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2010 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Germany; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neovascularization, Pathologic; Ovarian Neoplasms; Proportional Hazards Models; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; ErbB Receptors; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Taxoids; Treatment Outcome | 2011 |
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; United States | 2010 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2010 |
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeu
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Gene Amplification; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Young Adult | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Radiotherapy Dosage; Severity of Illness Index; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Time Factors | 2011 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Comorbidity; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Nursing Assessment; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pain Measurement; Reproducibility of Results; Risk Factors; Taxoids | 2011 |
Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome; Tumor Burden | 2011 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Docetaxel; Dyspnea; Female; Humans; Lung Neoplasms; Male; Survival Rate; Taxoids | 2012 |
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Quality of Life; Recurrence; Severity of Illness Index; Taxoids | 2011 |
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Quality of Life; Sulfonamides; Taxoids | 2011 |
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Taxoids | 2011 |
Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Dyspnea; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukopenia; Levofloxacin; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ofloxacin; Pain; Taxoids | 2011 |
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nervous System Diseases; Ovarian Neoplasms; Prospective Studies; Quality of Life; Survival Rate; Taxoids | 2012 |
Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus paraaortic irradiation for stage III endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids | 2012 |
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2012 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Taxoids | 2012 |
A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Fatigue; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Preoperative Period; Recombinant Proteins; Taxoids; Thrombocytopenia; Treatment Outcome | 2013 |
Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Taxoids | 2012 |
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2012 |
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Premenopause; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vomiting | 2012 |
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of su
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Thiotepa | 2013 |
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Republic of Korea; Taxoids; Treatment Outcome | 2013 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Heart; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2013 |
Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Risk Assessment; Smoking; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2013 |
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chills; Docetaxel; Dysgeusia; Female; Fever; Genetic Therapy; Humans; Hypotension; Interleukin-12; Middle Aged; Nausea; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Plasmids; Taxoids | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Taxoids; Treatment Outcome | 2013 |
Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Japan; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Serine; Taxoids; Young Adult | 2014 |
Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Paclitaxel; Pemetrexed; Prognosis; Proportional Hazards Models; Taxoids; Treatment Outcome | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2015 |
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Interactions; Electrocardiography; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab | 2014 |
[Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclobutanes; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids | 2014 |
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Somatosensory Disorders; Taxoids; Treatment Outcome; Young Adult | 2014 |
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Patient Compliance; Taxoids; Young Adult | 2015 |
Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: a randomized, phase III study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Taxoids; Tumor Necrosis Factor-alpha | 2015 |
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Docetaxel; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Prospective Studies; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Tissue Array Analysis | 2015 |
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cation Transport Proteins; Copper-Transporting ATPases; Docetaxel; Female; Gastrointestinal Diseases; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; NAV1.8 Voltage-Gated Sodium Channel; Ovarian Neoplasms; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Risk Factors; Scotland; Severity of Illness Index; Taxoids; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Everolimus; Humans; Male; Neoplastic Cells, Circulating; Phosphorylation; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins | 2015 |
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Induction Chemotherapy; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2016 |
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Diarrhea; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proanthocyanidins; Prognosis; Quality of Life; Taxoids; Trastuzumab; Young Adult | 2017 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Receptor, ErbB-2; Taxoids; Trastuzumab | 2017 |
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Taxoids; Trastuzumab | 2017 |
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Animals; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Hypothermia, Induced; Induction Chemotherapy; Middle Aged; Paclitaxel; Quality of Life; Scalp; Taxoids; Trastuzumab | 2018 |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Breast Neoplasms; Canada; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Europe; Female; Humans; Maytansine; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2018 |
Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Uterine Cervical Neoplasms | 2018 |
Responses to carboplatin in BRCA1/2-mutated breast cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Carboplatin; Docetaxel; Female; Germ-Line Mutation; Humans; Prognosis; Treatment Outcome; Triple Negative Breast Neoplasms; United Kingdom | 2018 |
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Female; Germ-Line Mutation; Humans; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Support Vector Machine; Trastuzumab; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2018 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclopentanes; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2019 |
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Postoperative Care; Recurrence; Risk Factors; Young Adult | 2019 |
A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Catheterization, Peripheral; Catheters, Indwelling; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Trastuzumab; Vascular Access Devices | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Pemetrexed | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2020 |
Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2020 |
Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Uterine Cervical Neoplasms | 2021 |
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Triple Negative Breast Neoplasms | 2022 |
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Tumor Microenvironment | 2022 |
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2023 |
Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
343 other study(ies) available for docetaxel anhydrous and carboplatin
| Article | Year |
|---|---|
[Recent advances in ovarian cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
Docetaxel: today's results and tomorrow's promises.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors | 1998 |
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Cells, Cultured; Cisplatin; Docetaxel; Drug Antagonism; Granulocytes; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Monocytes; Paclitaxel; Polysorbates; Taxoids | 1999 |
Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Colony-Forming Units Assay; Docetaxel; Female; Humans; Linear Models; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Interactions; Flow Cytometry; Humans; Lung Neoplasms; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Cells, Cultured | 1999 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |
[A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Pulmonary Alveoli; Taxoids; Tegafur; Uracil | 2000 |
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carboplatin; Docetaxel; Female; Humans; Kidney; Kinetics; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Regression Analysis; Spectrophotometry, Atomic; Taxoids; Time Factors | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Ifosfamide; Methotrexate; Mice; Mice, Nude; Paclitaxel; Survival Rate; Taxoids | 2001 |
[A case of adrenal metastasis of lung cancer treated by carboplatin and docetaxel].
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Paclitaxel; Taxoids | 2001 |
[Combination chemotherapy of carboplatin and docetaxel for advanced non-small cell lung cancer (NSCLC)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
The integration of docetaxel into first-line chemotherapy for ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2001 |
Docetaxel/carboplatin combination produces impressive response in ovarian cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Combined Modality Therapy; Docetaxel; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Paclitaxel; Taxoids | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Drug Costs; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Sensitivity and Specificity; Survival Rate; Taxoids | 2002 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infection Control; Infections; Inflammation; Melphalan; Middle Aged; Mitoxantrone; Mucous Membrane; Multivariate Analysis; Neutropenia; Paclitaxel; Patient Selection; Retrospective Studies; Risk; Taxoids; Thiotepa; Transplantation Conditioning | 2001 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
[A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids | 2002 |
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Camptothecin; Carboplatin; Clinical Trials, Phase I as Topic; Computer Simulation; Dexamethasone; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Maximum Tolerated Dose; Monte Carlo Method; Paclitaxel; Taxoids; Zoledronic Acid | 2002 |
[Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Humans; Laser Therapy; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Pneumonectomy; Taxoids; Tracheal Neoplasms | 2002 |
Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colectomy; Colon; Colonic Neoplasms; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Paclitaxel; Taxoids; Time Factors; Vincristine | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Two patients with distant metastases from head and neck squamous cell carcinomas successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Remission Induction; Taxoids | 2003 |
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 2003 |
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids | 2003 |
Cervical adenocarcinoma treated with docetaxel and carboplatin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Fatal Outcome; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Taxoids; Uterine Cervical Neoplasms | 2003 |
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mesentery; Neoplasm Recurrence, Local; Pelvic Neoplasms; Retroperitoneal Neoplasms; Taxoids; Tomography, X-Ray Computed | 2004 |
[The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Taxoids; Thrombopoietin | 2003 |
[Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Taxoids | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids; Treatment Outcome | 2004 |
Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fever; Genital Neoplasms, Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 2004 |
Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB.
Topics: Acute Disease; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Docetaxel; Humans; Karyotyping; Leukemia, Myeloid; Lung Neoplasms; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Taxoids | 2004 |
Correspondence re L. J. Wirth et al., Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res 2003;9:1698-704.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Remission Induction; Taxoids; Time Factors; Treatment Outcome | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
[Docetaxel and carboplatin for epithelial ovarian cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Taxoids | 2004 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Humans; Ligation; Male; Middle Aged; Neoplasm Metastasis; Parenteral Nutrition, Total; Peritoneovenous Shunt; Pleural Effusion; Postoperative Complications; Respiration, Artificial; Taxoids; Thoracostomy; Thoracotomy; Tissue Adhesives | 2004 |
[Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2004 |
[Combination chemotherapy with docetaxel+carboplatin in the treatment of cancer of the ovary and fallopian tube].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Edema; Fallopian Tube Neoplasms; Female; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Peripheral Nervous System Diseases; Taxoids | 2004 |
Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cimetidine; Cisplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Drug Synergism; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2004 |
Necessity of identifying the patterns of failure after concurrent radiochemotherapy part of a combined modality approach in patients with stage III non-small cell lung cancer [Sakai et al., Lung Cancer 2004;43:195-201].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Patient Care Planning; Prognosis; Taxoids; Treatment Outcome | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Estradiol; Female; Fluorouracil; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Herceptin and chemotherapy combination active in advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2004 |
The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma; Docetaxel; Fatal Outcome; Female; Humans; Meningitis; Middle Aged; Ovarian Neoplasms; Recurrence; Taxoids | 2005 |
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Epithelial Cells; Female; Hemoglobins; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2005 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer.
Topics: Aged; Alleles; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Carboplatin; Codon; DNA; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, p53; Germ-Line Mutation; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Mutation, Missense; Myelodysplastic Syndromes; Ovarian Neoplasms; Ovariectomy; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Skin; Taxoids | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Suramin; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
[Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Docetaxel; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids; Treatment Outcome | 2005 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; Drug Combinations; Drug Screening Assays, Antitumor; Fluorouracil; Infusions, Parenteral; Mice; Mice, Nude; Neoplasm Seeding; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2005 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |
[Central diabetes insipidus caused by pituitary metastasis of lung cancer].
Topics: Adenocarcinoma; Aged; Antidiuretic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deamino Arginine Vasopressin; Diabetes Insipidus, Neurogenic; Docetaxel; Humans; Lung Neoplasms; Male; Paclitaxel; Pituitary Neoplasms; Radiosurgery; Taxoids | 2005 |
Ultrasonographic guidance for spinal extracranial radiosurgery: technique and application for metastatic spinal lesions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phantoms, Imaging; Radiosurgery; Spinal Neoplasms; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2001 |
[Successful chemotherapy with carboplatin and docetaxel for an elderly patient with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quality of Life; Taxoids | 2006 |
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Longitudinal Studies; Lung Neoplasms; Lymphatic Metastasis; Pamidronate; Taxoids; Treatment Outcome | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Gene Frequency; Genetic Variation; Genotype; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Taxoids; Treatment Outcome | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Sulfonamides; Taxoids; Tubulin | 2006 |
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids | 2006 |
A prospective investigation of chemotherapy-induced neutropenia and quality of life.
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Cisplatin; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Prednisone; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Regression Analysis; Severity of Illness Index; Sickness Impact Profile; Taxoids; Treatment Outcome; United States; Vincristine | 2006 |
Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Papillary; Deoxycytidine; Diagnostic Errors; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Seminoma; Skin Neoplasms; Taxoids; Testicular Neoplasms; Thyroid Neoplasms; Thyroidectomy; Unnecessary Procedures | 2006 |
Docetaxel and beyond.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Extreme drug resistance is common after prior exposure to paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Neoadjuvant combination for stage II-III breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Humans; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Trastuzumab | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Diabetes Mellitus; Docetaxel; Echocardiography; Electrocardiography; Enalapril; Fatal Outcome; Glyburide; Heart Neoplasms; Humans; Hypertension; Hypoglycemic Agents; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Radiotherapy; Taxoids; Tomography, X-Ray Computed | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Survival Rate; Taxoids | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Survival Analysis; Taxoids | 2008 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.
Topics: Antineoplastic Agents; Carboplatin; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gemcitabine; HeLa Cells; Humans; Hyperthermia, Induced; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Taxoids; Temperature; Vinblastine; Vinorelbine | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Endpoint Determination; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 2008 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Lung Neoplasms; Male; Retrospective Studies; Taxoids | 2008 |
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2008 |
[Resected lung cancer with production of CA19-9].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carboplatin; Combined Modality Therapy; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Pneumonectomy; Taxoids; Treatment Outcome | 2008 |
Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Eruptions; Ectropion; Edema; Erythema; Humans; Male; Middle Aged; Taxoids | 2008 |
TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53; Young Adult | 2009 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids; Young Adult | 2009 |
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Taxoids | 2009 |
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Etoposide; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2009 |
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Taxoids; Young Adult | 2009 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Taxoids; Tumor Burden | 2010 |
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Taxoids; Thrombocytopenia; Trastuzumab | 2009 |
Two brothers with ataxia-telangiectasia-like disorder with lung adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Agents; Ataxia Telangiectasia; Autopsy; CA-125 Antigen; Carboplatin; Child; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Drug Therapy, Combination; Fatal Outcome; Humans; Lung Neoplasms; Male; MRE11 Homologue Protein; Mutation; Siblings; Taxoids | 2009 |
[Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Monitoring, Physiologic; Nephritis; Renal Dialysis; Taxoids | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Impact of incidental irradiation on clinically uninvolved nodal regions in patients with advanced non-small-cell lung cancer treated with involved-field radiation therapy: does incidental irradiation contribute to the low incidence of elective nodal failu
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Taxoids | 2010 |
Cytokeratin expression patterns in multiple infundibulocystic basal cell carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Basal Cell; Docetaxel; Female; Humans; Immunohistochemistry; Irinotecan; Keratins; Lung Neoplasms; Neoplasms, Second Primary; Skin Neoplasms; Taxoids | 2011 |
Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2010 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
[Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2009 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
Docetaxel, carboplatin and 5-fluorouracil (TCF) chemotherapy in patients with unresectable metastatic carcinoma of cervix.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Taxoids; Uterine Cervical Neoplasms | 2010 |
Primary chemotherapy patterns for ovarian cancer treatment in Japan.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Databases, Factual; Docetaxel; Evidence-Based Medicine; Female; Humans; International Classification of Diseases; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Taxoids; Treatment Outcome | 2009 |
Determining the role of radiotherapy in the adjuvant management of gastric cancer: an ocean apart.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Diarrhea; Docetaxel; Greece; Humans; Kaplan-Meier Estimate; Neutropenia; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 2009 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Patient Selection; Probability; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cell Proliferation; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Carboplatin and docetaxel-induced acute pancreatitis: brief report.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Pancreatitis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Tomography, X-Ray Computed | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids | 2010 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cholecalciferol; Docetaxel; Drug Eruptions; Dysgeusia; Female; Humans; Middle Aged; Stomatitis; Taxoids; Trastuzumab; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Vitamins | 2011 |
[Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2010 |
Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chromosome Mapping; Comparative Genomic Hybridization; Cystadenocarcinoma, Serous; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Profiling; Humans; Ovarian Neoplasms; Pilot Projects; Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Cell Line, Tumor; Docetaxel; Female; Flow Cytometry; Humans; Mice; Ovarian Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |
The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Drug Eruptions; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Neoplasm Metastasis; Recurrence; Taxoids | 2011 |
Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Carboplatin; Docetaxel; Female; Gestational Age; Maternal-Fetal Exchange; Models, Animal; Paclitaxel; Papio; Placenta; Pregnancy; Pregnancy, Animal; Taxoids; Trastuzumab | 2010 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
[Improvement of drug therapy for advanced gastric cancer used at a municipal clinical dispensary].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Carboplatin; Cisplatin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Russia; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Pneumonitis; Survival Rate; Taxoids | 2012 |
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2011 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Surveys and Questionnaires; Taxoids | 2012 |
Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Bystander Effect; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Profiling; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Humans; Ovarian Neoplasms; Prodrugs; Proteomics; Purine-Nucleoside Phosphorylase; Taxoids; Transduction, Genetic | 2011 |
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Topics: Adjuvants, Immunologic; Biomarkers, Tumor; CA-125 Antigen; Cancer Vaccines; Carboplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy, Active; Membrane Proteins; Middle Aged; Omentum; Ovarian Neoplasms; Paclitaxel; Peptide Fragments; Peritoneal Neoplasms; Taxoids; Tumor Burden; Vaccines, Subunit; WT1 Proteins | 2011 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine | 2011 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Radioimmunotherapy; Radiotherapy; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2011 |
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2012 |
A case of primary retroperitoneal serous adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Retroperitoneal Neoplasms; Taxoids | 2011 |
In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Docetaxel; ErbB Receptors; Genes, ras; Humans; Irinotecan; Male; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Which is the best foot to put forward in recurrent ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Taxoids | 2012 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cyclophosphamide; Disease Progression; Docetaxel; Female; Genes, erbB-2; Humans; Taxoids; Time Factors; Trastuzumab | 2011 |
[Concurrent chemoradiotherapy with carboplatin and docetaxel for stage III non-small-cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids | 2011 |
Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; China; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Panitumumab; Papillomavirus Infections; Proportional Hazards Models; Radiation Tolerance; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Failure | 2012 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Costs; Female; Humans; Markov Chains; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids; United States | 2012 |
Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Heart Failure; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mastectomy; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabine; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Deglutition Disorders; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Perforation; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prosthesis Failure; Retrospective Studies; Stents; Taxoids | 2012 |
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab | 2012 |
Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; HIV; HIV Infections; Humans; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Vulvar Neoplasms | 2012 |
Multi-institutional analysis of early glottic cancer from 2000 to 2005.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Tegafur; Time Factors; Uracil | 2012 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Male; Middle Aged; Neck Dissection; Neoplasm Staging; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Cisplatin; DNA-Binding Proteins; Docetaxel; Female; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation, Missense; Ovarian Neoplasms; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polymorphism, Genetic; Prospective Studies; Risk; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2013 |
Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity.
Topics: Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Follow-Up Studies; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Parotid Neoplasms; Photosensitivity Disorders; Positron-Emission Tomography; Radiosurgery; Risk Assessment; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Endoscopy; Feasibility Studies; Female; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Pharyngeal Neoplasms; Positron-Emission Tomography; Remission Induction; Salvage Therapy; Survival Rate; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Palliative Care; Radiotherapy; Retrospective Studies; Sex Factors; Taxoids | 2013 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |
Pyomyositis associated with chemotherapy for endometrial cancer: a case report.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Drainage; Endometrial Neoplasms; Female; Humans; Middle Aged; Prognosis; Pyomyositis; Taxoids | 2013 |
Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2013 |
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Receptor, ErbB-2; Taxoids; Thrombotic Microangiopathies; Trastuzumab | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Large-cell neuroendocrine carcinoma of prostate. Case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Neuroendocrine; Combined Modality Therapy; Docetaxel; Fatal Outcome; Humans; Immunohistochemistry; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2013 |
[Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Paclitaxel; Prednisolone; Prostatic Neoplasms; Taxoids | 2013 |
Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Equipment Design; Gemcitabine; Nebulizers and Vaporizers; Paclitaxel; Taxoids | 2013 |
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Feasibility Studies; Female; Humans; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cross-Sectional Studies; Desensitization, Immunologic; Docetaxel; Drug Eruptions; Etoposide; Female; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Skin Tests; Taxoids | 2015 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Carboplatin; Carcinogenesis; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Laryngeal Neoplasms; Mice; Neoplastic Stem Cells; Peptides; Polycomb Repressive Complex 1; Taxoids | 2015 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Pharyngeal Neoplasms; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy: a bi-institutional case series.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Spinal Cord Neoplasms; Spine; Taxoids | 2015 |
Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer.
Topics: Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Docetaxel; Drugs, Investigational; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Retrospective Studies; Taxoids; Trastuzumab | 2015 |
Ramucirumab combination improves OS and PFS in NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Lung Neoplasms; Paclitaxel; Ramucirumab; Stomach Neoplasms; Survival Analysis; Taxoids | 2014 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Retinoblastoma Protein; Survival Rate; Taxoids; Young Adult | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Endoscopy; Ethmoid Sinus; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nasal Cavity; Neoplasm Staging; Nose Neoplasms; Organoplatinum Compounds; Otorhinolaryngologic Surgical Procedures; Paranasal Sinus Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cross-Sectional Studies; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Sensitivity and Specificity; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2015 |
Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Leucovorin; Male; Middle Aged; Palliative Care; Remission Induction; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Creatinine; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms | 2015 |
Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Density; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mammary Glands, Human; Mammography; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Humans; Ovarian Neoplasms; RNA, Long Noncoding; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Itraconazole; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chromogranin A; Disease Progression; Disease-Free Survival; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Controlled Before-After Studies; Differential Threshold; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Olfaction Disorders; Pharyngeal Neoplasms; Prospective Studies; Sensory Thresholds; Smoking; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2016 |
Anaplastic Thyroid Carcinoma, Version 2.2015.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Doxorubicin; Humans; Paclitaxel; Radiotherapy, Intensity-Modulated; Taxoids; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Thyroidectomy | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Survival Rate; Taxoids; Young Adult | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Case-Control Studies; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Gamma Rays; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Risk; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
Topics: Adenocarcinoma; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Genes, BRCA2; Humans; Male; Middle Aged; Mutation; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Ovarian Neoplasms; RNA Stability; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Taxoids | 2016 |
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
Topics: Adult; BRCA1 Protein; BRCA2 Protein; Carboplatin; Clinical Trials as Topic; Docetaxel; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2016 |
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2016 |
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Multivariate Analysis; Neoadjuvant Therapy; Neutrophils; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Combined Modality Therapy; Docetaxel; Female; Filgrastim; Genes, BRCA1; Genes, BRCA2; Humans; Kansas; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Observational Studies as Topic; Polyethylene Glycols; Prospective Studies; Spain; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Registries; Retrospective Studies; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pancreatitis; Taxoids | 2017 |
Myelosuppression by chemotherapy in obese patients with gynecological cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Ideal Body Weight; Japan; Middle Aged; Obesity; Paclitaxel; Retrospective Studies; Taxoids; Thinness; Young Adult | 2016 |
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2016 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cytokines; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Interleukin-1beta; Interleukin-6; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal Neoplasms; Oropharyngeal Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Saliva; Severity of Illness Index; Stomatitis; Taxoids; Time Factors; Tumor Necrosis Factor-alpha | 2016 |
Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Docetaxel; Half-Life; Injections, Subcutaneous; Lymph; Male; Rats, Sprague-Dawley; Taxoids | 2016 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2017 |
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Prognosis; Taxoids | 2017 |
Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Combinations; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Pyridines; Ribonucleoside Diphosphate Reductase; Taxoids; Tegafur; Thymidylate Synthase; Tubulin; Tumor Suppressor Proteins | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Everolimus; Fluorouracil; Gene Expression; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Mice; Mice, Inbred NOD; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Xenograft Model Antitumor Assays | 2017 |
On Uterine Angiosarcomas: 2 Additional Cases.
Topics: Antineoplastic Agents; Carboplatin; Disease-Free Survival; Docetaxel; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Neoplasms; Uterus | 2017 |
Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Topics: Administrative Claims, Healthcare; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Comparative Effectiveness Research; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Medicare; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Propensity Score; Retrospective Studies; SEER Program; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2017 |
[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Taxoids; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Retrospective Studies; Taxoids | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Colony-Stimulating Factors; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Receptor, ErbB-2; Trastuzumab | 2018 |
Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cisplatin; DNA Breaks, Double-Stranded; DNA-Activated Protein Kinase; DNA, Neoplasm; Docetaxel; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Ku Autoantigen; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Small Cell Lung Carcinoma; Taxoids | 2018 |
Chondritis of the ear after docetaxel-carboplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged | 2019 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Disease-Free Survival; Docetaxel; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2016 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Pleural Effusion, Malignant; Small Cell Lung Carcinoma | 2018 |
Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
Topics: Breast Neoplasms; Carboplatin; Colony-Stimulating Factors; Docetaxel; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2018 |
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Oxaliplatin; Paclitaxel; Premedication; Retrospective Studies; Tertiary Care Centers | 2019 |
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carboplatin; Cell Proliferation; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2018 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cohort Studies; Docetaxel; Female; Humans; Incidence; Medicare; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; SEER Program; United States | 2019 |
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bevacizumab; Carboplatin; Chemoradiotherapy; Docetaxel; Fistula; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Treatment Outcome | 2018 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Piperazines; Protein Kinase Inhibitors | 2019 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Emergencies; Female; Fever; Hospitalization; Humans; Infections; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Mastectomy, Segmental; Middle Aged; Neutropenia; New South Wales; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Trastuzumab | 2019 |
What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bone Neoplasms; Brain Neoplasms; Carboplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pemetrexed; Prognosis | 2019 |
In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Case-Control Studies; Cesarean Section; Cohort Studies; Congenital Abnormalities; Continuous Positive Airway Pressure; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Labor, Induced; New Zealand; Paclitaxel; Perinatal Death; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Prospective Studies; Respiratory Distress Syndrome, Newborn; Stillbirth; Tamoxifen; Trastuzumab | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
Topics: Adult; Agammaglobulinemia; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Gram-Positive Bacterial Infections; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2020 |
Hyperpolarized
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbon Isotopes; Carboplatin; Docetaxel; Feasibility Studies; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Prognosis; Prostatic Neoplasms; Pyruvic Acid; Survival Rate | 2020 |
Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Ovarian Neoplasms; Pregnancy; Pregnancy Complications; Treatment Outcome | 2019 |
Classification of three prognostically different groups of head and neck cancer patients based on their metabolic response to induction chemotherapy (IC-1).
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Patient Selection; Positron Emission Tomography Computed Tomography; Retrospective Studies; Surgical Procedures, Operative; Survival Analysis; Treatment Outcome | 2020 |
Consolidation chemotherapy in early-stage cervical cancer patients with lymph node metastasis after radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Consolidation Chemotherapy; Docetaxel; Female; Humans; Hysterectomy; Liposomes; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2020 |
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Markov Chains; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Progression-Free Survival; Quality of Life; Receptor, ErbB-2; Trastuzumab | 2020 |
Doublet therapy effective in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Pemetrexed | 2020 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2020 |
Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carboplatin; Docetaxel; Drug Therapy, Combination; Humans; Male; Meta-Analysis as Topic; Prostatic Neoplasms, Castration-Resistant; Systematic Review as Topic; Treatment Outcome | 2020 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Ovary; Paclitaxel; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2020 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Chromosomes, Human, Pair 17; Docetaxel; Female; Gene Amplification; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; Carboplatin; Cyclin-Dependent Kinases; Docetaxel; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center.
Topics: Adult; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Zoledronic Acid | 2022 |
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Doxorubicin; Female; Humans; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy in Laryngeal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2021 |
[Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Topics: Adenocarcinoma of Lung; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Crizotinib; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Male; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2021 |
[Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers, Tumor; Carboplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Nomograms; Support Vector Machine; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Mastectomy; Neoadjuvant Therapy; Retrospective Studies; Trastuzumab | 2022 |
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
Topics: Apoptosis; Autophagy; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Docetaxel; Female; Giant Cells; Humans; Hydroxychloroquine; Nelfinavir; Ovarian Neoplasms; Polyploidy; Sirolimus | 2022 |
Inhibitory effects and gene expression analysis of chemotherapeutic photodynamic therapy by using a liposomally formulated indocyanine green derivative.
Topics: Animals; Carboplatin; Cell Line, Tumor; Docetaxel; Gene Expression; Indocyanine Green; Mice; Photochemotherapy; Photosensitizing Agents | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2022 |
PROSPECTS OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER AS A METHOD OF IMPROVING SURVIVAL.
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2022 |
[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor].
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Nivolumab; Pemetrexed; Survivors | 2022 |
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Topics: Adult; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies; Scalp; Taxoids | 2022 |
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Efficacy of chemotherapies for unresectable extramammary Paget disease: a single-centre retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Fluorouracil; Humans; Paget Disease, Extramammary; Retrospective Studies | 2023 |
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; BRCA1 Protein; BRCA2 Protein; Carboplatin; DNA Damage; Docetaxel; Humans; Triple Negative Breast Neoplasms | 2023 |
Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix.
Topics: Carboplatin; Carcinoma; Cervix Uteri; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Hysterectomy; Lymphatic Metastasis; Neoplasm Staging; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2023 |
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
Topics: Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Trastuzumab | 2023 |